The maintenance of a Buy rating and a $31 price target by Chardan Capital, as reiterated by analyst Keay Nakae, suggests a strong confidence in Dyne Therapeutics' potential for growth. This endorsement could positively influence investor sentiment and potentially drive up the stock price in the short term.